Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double‐blind, controlled trial
Hisashi Hidaka(Kitasato University), Takumi Igura, Keiji Tsuji(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Shingo Asahara(Fukuoka Tokushukai Hospital), Shigehiro Kokubu, Namiki Izumi(Musashino Red Cross Hospital), Kazuo Notsumata(Fukui-ken Saiseikai Hospital), Shinji Katsushima(Kyoto Medical Center), Tomohiko Akahoshi(Kyushu University), Hirofumi Kawanaka(Kyushu University), Shoichi Matsutani(Chiba University), Yukio Osaki(Osaka Red Cross Hospital), Takahiro Sato(Sapporo Kosei General Hospital), Shozo Hirota(Hyogo Medical University)
Cited by 57
Related Papers
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586